Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Teva Pharmaceutical Industries Ltd. (TEVA) vs Viatris Inc. (VTRS)

Teva Pharmaceutical Industries Ltd. and Viatris Inc. are both Drug Manufacturers Specialty & Generic companies. Teva Pharmaceutical Industries Ltd. is the larger, with a market value of $46.9B against $20.0B — 2.3× the size. Viatris Inc. has negative trailing earnings, so its P/E is not meaningful; Teva Pharmaceutical Industries Ltd. trades at 62.2×. Viatris Inc. grew revenue faster over the last twelve months: 4.40% against 4.13%. Teva Pharmaceutical Industries Ltd. has the higher net margin (4.08% vs −2.79%) and the higher return on invested capital (4.58% vs −0.20%). Across the 20 metrics below, Viatris Inc. leads on 11 and Teva Pharmaceutical Industries Ltd. on 9.

Valuation

Metric TEVA VTRS Drug Manufacturers Specialty & Generic median
P/E 62.21 n/m 20.14
P/S 2.64 1.41 2.25
P/B 5.89 1.45 1.90
Price to free cash flow 32.59 10.97 16.54
EV/EBITDA 23.38 12.22 12.29
EV/Sales 3.38 2.25 2.56
Earnings yield 1.61% (2.02%) (2.99%)
Free cash flow yield 3.07% 9.11% 0.00%

Profitability

Metric TEVA VTRS Drug Manufacturers Specialty & Generic median
Gross margin 52.46% 34.83% 53.94%
Operating margin 8.77% (0.59%) 0.00%
Net margin 4.08% (2.79%) 0.00%
Free cash flow margin 8.09% 12.83% 0.00%
Return on equity 9.69% (2.75%) (0.40%)
Return on assets 1.77% (1.12%) (3.32%)
Return on invested capital 4.58% (0.20%) 0.00%

Growth

Metric TEVA VTRS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 4.13% 4.40% 10.01%
EPS growth (last fiscal year) 183.45% (466.04%) —
Revenue growth, 5-year CAGR 0.71% 3.66% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TEVA VTRS Drug Manufacturers Specialty & Generic median
Debt to equity 2.14 0.94 0.05
Current ratio 0.88 1.58 2.31
Net debt to EBITDA 4.19 4.92 0.85

Dividend

Metric TEVA VTRS Drug Manufacturers Specialty & Generic median
Dividend yield — 4.15% 1.70%
Payout ratio 0.00 0.31 0.00

Size

Metric TEVA VTRS Drug Manufacturers Specialty & Generic median
Market cap 46.87b 19.99b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack